Chickenpox: all 156 studies

Page 1 of 2. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.

• Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled TrialNot yet recruitingNCT07818356Phase 4
• Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveRecruitingNCT07817108Phase 3
• A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNot yet recruitingNCT07742644Phase 3
• Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and AboveNot yet recruitingNCT07481604Phase 2
• Second Dose of Varicella Vaccine in Healthy ChildrenRecruitingNCT07475000Phase 3
• Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese ChildrenNot yet recruitingNCT07473427Phase 3
• Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ TransplantationNot yet recruitingNCT07443709Phase 2
• SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsRecruitingNCT07415252Phase 3
• A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of AgeRecruitingNCT07406360Phase 3
• Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
• A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsNot yet recruitingNCT07205796Phase 2
• A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 YearsRecruitingNCT07054099Phase 3
• Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care SettingRecruitingNCT07047053
• Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP VaccineNot yet recruitingNCT06891872Phase 4
• A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of AgeRecruitingNCT06855160Phase 3
• A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of AgeRecruitingNCT06806137Phase 3
• A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of AgeRecruitingNCT06740630Phase 3
• A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeRecruitingNCT06693895Phase 3
• An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella VaccineEnrolling by invitationNCT06484686Phase 4
• Correlation of Protection Against Varicella in an Exploratory StudyNot yet recruitingNCT06482216
• A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult SubjectsyRecruitingNCT06068608Phase 1
• Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingNCT05952505Phase 4
• Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella VaccinationRecruitingNCT05422508Phase 2
• An Immunity Persistence Study of Live Attenuated Varicella VaccineEnrolling by invitationNCT05095701Phase 4
• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldEnrolling by invitationNCT05015686Phase 3
• Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation RecipientsRecruitingNCT00492739Phase 2/3
• A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeCompletedNCT05630846Phase 2Results posted
• A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of AgeCompletedNCT05084508Phase 2Results posted
• Systems Biology of Zoster VaccineCompletedNCT04047979Phase 2Results posted
• Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)CompletedNCT03843632Phase 3Results posted
• Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)CompletedNCT03239873Phase 3Results posted
• A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.CompletedNCT02570126Phase 3Results posted
• Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)CompletedNCT02062502Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3Results posted
• Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 3Results posted
• Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)CompletedNCT01390857Results posted
• Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVCompletedNCT01190228Phase 3Results posted
• Re-examination Study For Varivax (V210-059 AM2)CompletedNCT01062061Results posted
• ProQuad Dose Selection Study (V221-011)(COMPLETED)CompletedNCT00986232Phase 2Results posted
• A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedNCT00985166Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedNCT00985153Phase 3Results posted
• ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedNCT00975507Phase 3Results posted
• Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 3Results posted
• Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working SeedsCompletedNCT00892775Phase 2Results posted
• A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)CompletedNCT00886613Phase 1Results posted
• A Study of ProQuad™ in Healthy Children in Korea (V221-023)TerminatedNCT00839917Phase 3Results posted
• Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)CompletedNCT00822237Phase 3Results posted
• Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).CompletedNCT00792623Phase 2Results posted
• Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of AgeCompletedNCT00578175Phase 2Results posted
• Study of Two Formulations of GSK Biologicals' Varicella VaccineCompletedNCT00568334Phase 2Results posted
• Safety Study of ProQuad® rHA in Infants (V221-037)CompletedNCT00560755Phase 3Results posted
• Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
• Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)CompletedNCT00432042Phase 3Results posted
• Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
• A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
• Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)CompletedNCT00326183Phase 4Results posted
• Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxCompletedNCT00226499Phase 3Results posted
• Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected PatientsCompletedNCT00127608Phase 3Results posted
• A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and OlderActive, not recruitingNCT07311148Phase 2
• Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveActive, not recruitingNCT07285278Phase 2
• Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveActive, not recruitingNCT07285265Phase 1
• Study on Booster Immunization With Varicella Vaccine at Different IntervalsCompletedNCT06994052Phase 4
• Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)CompletedNCT06987942Phase 4
• Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing ProgramCompletedNCT06901362
• Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 YearsCompletedNCT06614816Phase 3
• A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 YearsCompletedNCT06592456Phase 3
• Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 YearsActive, not recruitingNCT06409494Phase 1
• A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy ParticipantsCompletedNCT06375512Phase 1
• Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesCompletedNCT06314724Phase 3
• PREPARE-iVAC TrialCompletedNCT05924685Phase 4
• A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of AgeActive, not recruitingNCT05839301Phase 3
• Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device.CompletedNCT05732337Not applicable
• The Influence of Trained Immunity in COVID-19 Vaccinated IndividualsStatus unknownNCT05705180
• A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy AdultsTerminatedNCT05703607Phase 1/2
• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccineActive, not recruitingNCT05669625Phase 3
• An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 YearsStatus unknownNCT05664152Not applicable
• Herpes Virus Infections in Kidney Transplant PatientsActive, not recruitingNCT05604911
• Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant StudyActive, not recruitingNCT05532540
• A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A VaccineCompletedNCT05526820Phase 4
• Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknownNCT05470855Phase 4
• Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster VirusStatus unknownNCT05460429Phase 4
• Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderActive, not recruitingNCT05304351Phase 2
• Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldCompletedNCT05158777Phase 3
• An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster ImmunizationCompletedNCT05150392Phase 3
• Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years OldCompletedNCT04384016Phase 4
• Pharmacokinetics of Valacyclovir Oral Solution in ChildrenTerminatedNCT04081480Not applicable
• A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella VaccineCompletedNCT03555071Phase 3
• Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster VirusStatus unknownNCT03509701
• Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A VaccineStatus unknownNCT03330171Phase 4
• Tzanck Smear With Methylene Blue Stain for HerpesStatus unknownNCT03178747Phase 3
• Safety Study of NBP608 in Healthy Adult VolunteersCompletedNCT03121638Phase 1
• The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of AgeCompletedNCT03114982Phase 2
• Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of AgeCompletedNCT03114943Phase 3
• A Blind, Randomized and Controlled Study of Live Attenuated Varicella VaccinesCompletedNCT02981836Phase 3
• A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and ChildrenCompletedNCT02965404Phase 1
• Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.WithdrawnNCT02692066
• Reactivation of Varicella Zoster Virus and Risk of Vascular DiseaseWithdrawnNCT02559596
• Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus VaccineStatus unknownNCT02514018Phase 4
• Review of Human Herpes Viruses in BurnsCompletedNCT02452229

← Chickenpox overview